The study conducted by Yale University aims to establish EIM as a non-invasive biomarker for assessing muscle involvement in IIMs, which includes conditions like dermatomyositis and polymyositis. The successful validation of EIM parameters could position this technology as a valuable diagnostic tool in the neuromuscular disorder market, which is characterized by a growing demand for innovative, non-invasive diagnostic methods. The competitive landscape includes traditional diagnostic methods such as muscle biopsies and electromyography, which are more invasive and may not provide real-time assessments. If EIM is proven effective, it could lead to significant market opportunities and partnerships in the diagnostics sector, particularly for companies focused on neuromuscular diseases.